News Endo gives way and withdraws opioid painkiller after FDA pre... Pharma makes decision after FDA intervenes to fight opioid crisis.
News As market declines, Purdue hopes to kick opiate habit Amid opiate crisis, Purdue looks for abuse-deterrent alternatives.
News Lilly beats Novo to China with an oral GLP-1 for obesity Lilly's orforglipron has been approved in China, becoming the first oral GLP-1 agonist to enter the Chinese weight management market.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.